Core Viewpoint - The Gross Law Firm is notifying shareholders of Caribou Biosciences, Inc. regarding a class action lawsuit due to alleged misleading statements and financial risks associated with the company's product CB-010 [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from July 14, 2023, to July 16, 2024 [2]. - Allegations include that Caribou overstated the safety, efficacy, and durability of CB-010 compared to approved therapies, and failed to disclose significant risks regarding cash and liquidity [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by February 24, 2025, to potentially become lead plaintiffs [3]. - Registration allows shareholders to receive updates on the case through portfolio monitoring software [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].
Caribou Biosciences, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU